Background and Purpose-It is currently unclear whether midlife systemic inflammation promotes the development of white matter (WM) abnormalities and small vessel disease in the elderly. We examined the association of midlife systemic inflammation with late-life WM hyperintensity volume, deep and periventricular WM microstructural integrity (fractional anisotropy and mean diffusivity [MD]), cerebral infarcts, and microbleeds in a biracial prospective cohort study. Methods-Linear and logistic regression examined the relation between midlife high-sensitivity C-reactive protein (CRP)-a nonspecific marker of inflammation-and brain magnetic resonance imaging markers assessed 21 years later in the Atherosclerosis Risk in Communities Study. Results-We included 1485 participants (baseline age, 56[5]; 28% black). After adjusting for demographic factors and cardiovascular disease, each SD increase in midlife CRP was associated with lower fractional anisotropy (−0.09 SD; 95% confidence interval, −0.15 to −0.02) and greater MD (0.08 SD; 95% confidence interval, 0.03-0.15) in deep WM and lower fractional anisotropy (−0.07 SD; 95% confidence interval, −0.13 to 0.00) in periventricular WM. We found stronger associations between CRP and periventricular WM microstructural integrity among black participants (P interaction=0.011). Although an association between higher CRP levels and greater WM hyperintensity volume was found only among APOE ε4-positive participants in our primary analysis (0.14 SD; 95% confidence interval, 0.01-0.26; P interaction=0.028), this relationship extended to the entire sample after accounting for differential attrition. Midlife CRP was not associated with the presence of cerebral infarcts or microbleeds in late life. Conclusions-Our findings support the hypothesis that midlife systemic inflammation may promote the development of chronic microangiopathic structural WM abnormalities in the elderly.
C erebral small vessel disease (SVD) and white matter (WM) abnormalities are highly prevalent among older adults and are associated with cognitive decline 1 and dementia. 2 Although several cross-sectional studies have found evidence for an association between systemic inflammation, SVD, 3 and reduced WM integrity 4 among older adults, the temporal relationship between systemic inflammation and each of these neurological changes is still not well understood. As such, it remains unclear whether systemic inflammation contributes to the early pathogenesis of WM changes and SVD or whether it is merely an associated feature or an epiphenomenon of these neurological processes.
An association between midlife systemic inflammation, greater late-life WM abnormalities, and increased risk for subsequent SVD would support an etiologic role of systemic inflammation in the development of structural brain abnormalities commonly observed in older adults. Thus, the goal of the current study was to examine the relationship between midlife high-sensitivity C-reactive protein (CRP)-a widely used marker of systemic inflammation-and late-life measures of WM hyperintensity (WMH) volume, WM microstructure, cerebral infarcts, and cerebral microbleeds (CMBs) in a large community sample of nondemented white and black adults. Given evidence that race 5 and APOE ε4 allele status 6 can influence the effect of inflammatory stimuli on vascular function, we also examined the modifying effect of each of these factors.
Methods

Study Population
The ARIC Study (Atherosclerosis Risk in Communities) is an ongoing community-based, prospective study, which initially enrolled 15 792 adults between the ages of 45 and 65. 7 Probability sampling was used to select participants from 4 communities within the United States: Washington County, MD; Forsyth County, NC; northwestern suburbs of Minneapolis, MN; and Jackson, MS. After the first visit (1987) (1988) (1989) , participants were seen for 3 additional in-person visits taking place ≈3 years apart until visit 4 (1996-1998) , and for a fifth visit in 2011 to 2013 (visit 5) .
A subset of participants completed a brain magnetic resonance imaging (MRI) at visit 5 1 . Participant selection was based on standard safety exclusion criteria and participation in the earlier ARIC Brain MRI Ancillary Study. Additionally, all participants who evidenced cognitive impairment at visit 5 and an age-stratified random sample of participants without evidence of cognitive impairment were selected to undergo brain MRI. Of the 1978 participants who completed a brain MRI at visit 5, we excluded 7 participants because of poor image quality or incomplete brain MRI data, 114 who met criteria for dementia, 94 for a diagnosis of a chronic inflammatory diseases (ie, systemic lupus erythematosus, gout), 11 because of intracranial abnormalities (ie, arteriovenous malformation, brain tumor, or significant space occupying lesion), 113 for missing CRP levels, 150 for missing ≥1 covariates, and 4 for race other than white or black.
The ARIC study protocols were approved by the institutional review boards at each participating center. All participants gave written informed consent at each study visit.
Inflammatory Marker Analysis
High-sensitivity CRP levels (mg/L) were measured in 2011 to 2013 using an immunoturbidimetric assay on the Roche Modular P chemistry analyzer (Roche Diagnostics, Indianapolis, IN) from serum samples originally collected at visit 2 (1990-1992 ) and stored at −70°C. We also conducted an exploratory analysis using a set of 5 less commonly used inflammatory biomarkers that were measured at visit 1, that is, fibrinogen (mg/dL), albumin (g/dL), VWF (von Willebrand factor; % of standard) and factor VIII activity (% of standard), and white blood cell count using standardized protocols described previously. 8 A visit 1 inflammation composite score was created by converting each of the 5 inflammatory markers to a standardized Z score and calculating the mean. Albumin values were multiplied by −1 before being included in the composite Z score.
Brain MRI
All brain MRIs were conducted at visit 5 using a 3T MRI. Details on MRI acquisition have been described previously. 1 The following sequences were obtained from all participants: MP-RAGE (magnetization-prepared rapid gradient-echo), Axial T2*GRE (gradient-echo), Axial T2 fluid-attenuated inversion recovery, and Axial diffusion tensor imaging. Cerebral infarctions and microbleeds were identified and measured by a trained imaging technician and confirmed by radiologists, as described previously. 1 Cortical infarctions were defined using fluid-attenuated inversion recovery sequences as a hyperintense lesion ≥5 mm in size in the greatest dimension in cortical grey matter, which may extend to underlying WM. Lacunar infarctions were defined as a hyperintense subcortical lesion with a dark center (≥3 and ≤15 mm in size) within the WM, infratentorial, or central grey/capsular regions that is distinguishable from perivascular space. CMBs were defined using a T2* GRE MRI sequence. WMH volume was derived from proton density-weighted images using a quantitative computer-aided segmentation program, which uses an algorithm to segment fluid-attenuated inversion recovery images (FLAIR-histoseg) and measure the volumetric burden of leukoaraiosis. 9 All analyses using WMH adjusted for total intracranial volume. To assess the overall burden of SVD, we created an SVD composite score, 10 which accounts for the presence of lacunar infarcts, CMBs, and elevated WMH burden (online-only Data Supplement). Diffusion tensor imaging measures of fractional anisotropy and mean diffusivity (MD) were used to assess microstructural integrity of lobar and deep WM regions. 11 Lower fractional anisotropy and higher MD reflect reduced coherence and microstructural integrity. The diffusion tensor imaging protocol is described in more detail in the online-only Data Supplement. We analyzed 2 regions of interest: total periventricular WM, and total deep subcortical WM. We reported standardized diffusion tensor imaging values for all analyses.
Covariates
Race-center (Washington County, white; Minnesota, white; Forsyth County, white; Forsyth County, black; and Jackson, black), sex, and years of education attained (less than high school, high school/ General Equivalency Diploma/vocational school, or any college) were determined by participant self-report at visit 1. Arthritis and other inflammatory conditions were assessed by self-report of physician diagnosis (present/absent) at visit 4. History of regular antiinflammatory medication use (eg, nonsteroidal anti-inflammatory drug, arthritis medication) was assessed at visit 5. All other covariates were assessed during visit 2, concurrent with the measurement of CRP levels. Alcohol and cigarette use (current/former/never) and cancer diagnoses were determined by participant self-report. Body mass index was calculated using recorded height and weight (kg/m 2 ). Hypertension was defined as systolic blood pressure >140 mm Hg, diastolic blood pressure >90 mm Hg, or use of hypertensive medication. Sitting diastolic and systolic blood pressures were calculated using a random zero sphygmomanometer. Second and third of 3 blood pressure measurements were averaged to define hypertension in the current analysis. Coronary heart disease was adjudicated based on participant self-report at visit 1 and a combination of self-report and medical record evidence of previous myocardial infarction, coronary artery bypass graft or angioplasty, or myocardial infarction determined by ECG between visits 1 and 2. Current anti-inflammatory medications were also recorded. APOE (0, 1, or 2 ε4 alleles) was genotyped using the TaqMan assay (Applied Biosystems, Foster City, CA). Dementia, used as an exclusionary criterion, was adjudicated by an expert committee based on a review of each participant's cognitive and functional status at visit 5.
Diabetes mellitus was defined as follows: fasting glucose ≥126 mg/ dL or nonfasting glucose of ≥200 mg/dL, current use of diabetes mellitus medication, or self-report of physician-diagnosed diabetes mellitus. The hexokinase method was used to measure serum glucose. The enzymatic method was used to measure total cholesterol and triglycerides. 12, 13 High-density lipoprotein cholesterol was measured after precipitation of non-high-density lipoprotein.
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Statistical Analysis
Participant characteristics were compared across CRP quartiles using 1-way ANOVA or χ 2 test. Because no evidence for nonlinear associations between CRP levels and MRI characteristics was found in exploratory analyses, we examined CRP as a linear continuous parameter. For all analyses, CRP values were log-transformed to correct for skewness. We used multivariable linear regression and logistic regression to evaluate the associations of CRP with MRI measures. All analyses were adjusted for the covariates listed in the previous section. We used multiplicative interaction terms to assess effect modification by race (white/black) and APOE ε4 allele status.
Sampling weights were incorporated to account for the ARIC brain MRI sampling strategy. Thus, the primary results represent estimates
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December 2017 using the entire ARIC visit 5 population. Sensitivity analyses were conducted using inverse probability of attrition weighting to understand the potential effects of differential attrition because of death or dropout; inverse probability of attrition weighting included modeling for both death and dropout. These weighting procedures correct for sampling bias by applying larger weights to participants with characteristics that make their inclusion in the analytic sample less likely.
In an attempt to isolate the effect of low-grade systemic inflammation, we also conducted a sensitivity analysis omitting participants with abnormally elevated CRP levels suggestive of an acute infection (>3 SD above the sample mean). Lastly, we also examined the effect of excluding participants with clinically defined stroke. Because outcome variables were correlated, we did not correct for multiple comparisons using Bonferroni correction. A 2-sided P value <0.05 was used as the cutoff for statistical significance. All analyses were conducted using Stata, version 14 (StataCorp, College Station, TX).
Results
Study Population Characteristics
In total, 1485 participants were included in this analysis. The mean age of the sample was 55.5 (5.2 SD) years at visit 2 and 76.2 (5.3 SD) years at visit 5. Sixty-two percent of the sample was female and 28% black. The mean time between the visit 2 CRP measurement and the visit 5 MRI was 21 years with little variation (0.9 SD). Participants with higher midlife CRP levels were more likely to be women, black, report a lower level of education, possess fewer copies of the APOE ε4 allele, possess higher levels of vascular risk factors, and be diagnosed with hypertension, heart failure, and arthritis (Table) .
Midlife Inflammation and Late-Life WMH Volume
Higher CRP levels were only marginally associated with greater WMH volume in our primary analysis ( Figure 1) ; however, a significant association was found between each SD increase in CRP level and greater WMH volume among participants with one ≥1 copy of the APOE ε4 allele (0.14 SD; 95% confidence interval, 0.01-0.26; P=0.032) but not among APOE ε4-negative participants (0.03 SD; 95% confidence interval, −0.06 to 0.11; P=0.522; P interaction=0.028; Table  I in the online-only Data Supplement). The magnitude of the association between higher CRP levels and larger WMH volume in the full sample was considerably stronger and statistically supported, after weighting analyses to account for differential attrition (Table II in the online-only Data Supplement). There was no evidence for effect modification by race. Associations were essentially unchanged in sensitivity analyses that omitted participants with clinical stroke and abnormally elevated inflammatory markers (Tables III and IV in the online-only Data Supplement).
Midlife Inflammation and Late-Life WM Microstructural Integrity
Higher midlife CRP levels were associated with lower fractional anisotropy and greater MD within deep WM (Figure 1 ).
In our multivariable regression model, the estimated reduction in deep WM microstructure per each SD increase in midlife CRP was similar to that for midlife hypertension and midlife diabetes mellitus. An association was also found between higher CRP levels and lower fractional anisotropy within periventricular WM, but this finding did not extend to MD. There was a significant race by CRP level interaction on MD within the periventricular WM (P interaction=0.011). The association between higher midlife CRP and reduced periventricular WM microstructural integrity was significantly stronger among black, compared with white, participants. In contrast, associations between CRP levels and deep WM microstructural integrity did not seem to differ by race. No evidence for effect modification by APOE ε4 status was found (Table I in the online-only Data Supplement). After accounting for differential attrition, associations between higher CRP levels and reduced periventricular microstructural integrity were strengthened, particularly among white participants (Table II in the online-only Data Supplement). Omitting participants with clinical stroke and abnormally elevated inflammatory markers did not substantively change the findings (Tables III  and IV in the online-only Data Supplement), but effect sizes were slightly attenuated after adjusting for WMH volume (Table V in the online-only Data Supplement).
Midlife Inflammation, Cerebral Infarcts, Microbleeds, and Composite SVD Among Older Adults
Cortical and lacunar infarcts and CMBs were present on MRI in 10% (n=148), 17% (n=257) and 25% (n=362) of participants, respectively (Table VI in the online-only Data Supplement). We found no association of midlife CRP levels with cortical or lacunar infarct presence, CMB presence, or SVD composite score in the total sample or in race-stratified analyses ( Figure 2 ). Interaction terms for race and APOE ε4 status did not reach statistical significance. Results were largely unchanged in sensitivity analyses (Figures I through III in the online-only Data Supplement).
Exploratory Analyses
Findings from our exploratory analyses that evaluated the association of visit 1 inflammation composite score with brain MRI markers were null ( Figure IV in the online-only Data Supplement; Table VII in the online-only Data Supplement).
Discussion
The current findings support an association between higher midlife CRP levels and reduced WM integrity in nondemented older adults. With regard to deep WM microstructural abnormalities, the effect of each SD increase in midlife CRP was similar to that of midlife hypertension and midlife diabetes mellitus. The associations between higher CRP and reduced WM microstructural integrity were largely independent of clinical stroke and remained significant after adjusting for WMH volume. An association between midlife CRP and latelife WMH volume was also found, but this relationship was restricted to participants who were APOE ε4 positive in our primary analysis. However, after accounting for differential attrition, the relationship between midlife CRP and late-life WMH volume was magnified and extended to the full sample, irrespective of APOE ε4 status. Importantly, all associations were independent of age, education, cardiovascular risk factors, and anti-inflammatory medication use. With regard to cerebrovascular disease, we found no relationship between higher midlife CRP levels and risk for lacunar infarcts, cortical infarcts, or CMBs in older adults. Although previous cross-sectional studies have demonstrated a link between systemic inflammation, reduced WM microstructural integrity, 4, 15 and greater WMH volume 3, 16 in older adults, it remains unknown whether systemic inflammation plays a pathogenic role in the development of these WM changes. By demonstrating an association between WM structural abnormalities among older adults and heightened systemic inflammation 2 decades earlier, our findings support the role of midlife systemic inflammation in the development of late-life WM pathology. Our finding that APOE ε4 allele possession magnifies the association between midlife systemic inflammation and later WMH volume could reflect a pattern of increased sensitivity to peripheral inflammatory signaling among APOE ε4 carriers. APOE ε4 allele possession has been associated with dysregulation of the NF-κB signaling pathway and increased levels of neuroinflammation in response to inflammatory stimuli. 17 However, the association of midlife CRP levels with late-life WMH volume was observed in APOE ε4 carriers and noncarriers alike after adjusting for differential death and dropout, suggesting that the modifying effect of APOE ε4 allele possession may also be explained, in part, by differential attrition. The role of Values are displayed as means (SD) and percentages. HDL indicates high-density lipoprotein; and LDL, low-density lipoprotein. *Assessed at visit 4 (1996-1998).
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APOE ε4 as a potential moderator will need to be clarified in future studies. We also found the association between higher CRP and reduced periventricular microstructural integrity to be stronger among black, compared with white, participants. Although racial differences in the response of vascular endothelial cells to peripheral inflammatory signaling 5 or the differential prevalence of moderating factors (eg, medical comorbidity) may account for some degree of the race-based differences, the reduction of these differences after adjusting for attrition suggests that this phenomenon may also result from dissimilar rates of death and dropout during the followup period.
Although the current study was conducted using a nondemented sample, our results suggest WM dysfunction may serve as a pathway through which midlife systemic inflammation increases one's risk for dementia. 18 The notion that cardiovascular disease during midlife influences late-life neurological outcomes has been borne out in recent epidemiological literature. 19, 20 Although we found associations between midlife CRP levels and late-life WM structural abnormalities that were independent of midlife cardiovascular disease, it remains possible that these associations are mediated, at least in part, by interim cardiovascular disease occurring after midlife. The observation that our results were largely unchanged after excluding participants with abnormally elevated inflammatory markers (suggestive of an acute inflammatory response) supports current theories, which posit that low-grade systemic inflammation alone may be enough to contribute to poor neurological outcomes. 21 It is possible that systemic inflammation represents a compensatory response or an epiphenomenon of another pathological process more directly linked to WM pathology. However, evidence that suggests that systemic inflammation can promote physiological processes believed to contribute to WM dysfunction, such as increased blood-brain barrier permeability 22 and microcirculatory dysfunction, 23 supports an etiologic contribution.
Although midlife CRP level was associated with WM integrity among older adults, it did not seem to be associated with cortical and lacunar infarcts or CMBs. Previous studies that have found an association between systemic inflammation, silent infarcts, and CMBs have been cross-sectional 3, 16, 24, 25 or have had relatively short follow-up periods. 26 It is possible that markers of systemic inflammation are only associated with cerebral infarcts or CMBs in older adults when inflammatory biomarkers are measured during late-life or at a time more proximal to the event. Additionally, the results of our exploratory analyses suggest that perhaps not all markers of midlife inflammation are associated with late-life neurological outcomes. However, we should note that the biomarkers used in our exploratory analyses are also regulated by nonimmune processes (eg, hemostatic, nutritional) and may, therefore, serve as less-specific indicators of low-grade systemic inflammation compared with CRP.
Strengths of the current study include its prospective design, use of a large community sample, inclusion of a relatively large group of black participants, and thorough assessment of potential confounding variables. However, the current findings should be interpreted within the context of several limitations. First, because we examined inflammatory markers assessed at a single time point, we were unable to examine the longitudinal properties of systemic inflammation, such as inflammation duration and trajectory, because they relate to neurological outcomes later in life. It is currently unclear whether elevations in a single inflammatory marker during midlife can be used as a surrogate marker for chronic systemic inflammation; however, evidence suggests CRP levels are relatively stable over time in absence of disease. 27 Second, although CRP is a widely used marker of systemic inflammation, there are several other inflammatory proteins, such as IL-6 (interleukin-6) and TNF-α (tumor necrosis factor-α), that are believed to more directly affect neurological functioning. Prospective studies which assay a wider selection of inflammatory markers will be needed. Third, we cannot rule out the possibility that the associations between CRP and measures of WM microstructural integrity were driven, at least in part, by macroscopic WM pathology (ie, leukoaraiosis), because we did not restrict our analyses to healthy-looking WM. Fourth, despite carefully adjusting for confounding demographic and clinical factors, it is still possible that our results are subject to residual confounding from unmeasured variables and the potential effects of treatment for medical conditions, such as hypertension. Lastly, the current findings are limited by the lack of serial MRIs, which precludes the assessment of change in our outcome variables over time. Because participants did not undergo an MRI at baseline, we cannot exclude the possibility that cerebrovascular disease and WM abnormalities were already present during midlife when systemic inflammation was assessed. Although some participants underwent an MRI at a previous visit, differences in imaging resolution prevent us from reliably examining change in MRI markers of interest. Despite these limitations, the current findings provide novel insight into the temporal relationship between systemic inflammation and brain health and add to the body of evidence implicating systemic inflammation in the pathogenesis of late-life WM dysfunction.
